^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BCA356

    i
    Other names: BCA356
    Company:
    Biocon
    Drug class:
    Carbonic anhydrase IX inhibitor, IL-12 modulator
    Related drugs:
    2years
    A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity (SITC 2022)
    Conclusions BCA356 specifically targets CAIX-expressing tumour cells and similar to wild type IL-12 cytokine, has the potential to reduce tumour proliferation with optimal activation of pro-inflammatory cytokines. Through these in vitro and in vivo studies, we demonstrate that BCA356 by its CAIX-targeted IL-12v delivery approach is both efficacious and safe.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • CA9 (Carbonic anhydrase 9) • STAT4 (Signal Transducer And Activator Of Transcription 4)
    |
    CD8 expression • CA9 overexpression • CA9 expression
    |
    BCA356